3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety and effectiveness of three week
daily subcutaneous injections of Parathyroid Hormone-related Protein (1-36). Previous studies
indicated that PTHrP has a skeletal 'anabolic' or bone-building effect, and has shown to
increase bone mineral density in postmenopausal women with osteoporosis. Safety of PTHrP will
be determined by measurements of blood pressure and pulse, serum blood calcium levels and
subjective symptoms. Effectiveness will be measured by changes in measurements of blood and
urine markers of bone turnover.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
Department of Health and Human Services National Institutes of Health (NIH)
Treatments:
Hormones Parathyroid Hormone Parathyroid Hormone-Related Protein